Maximum tolerated dose versus metronomic scheduling in the treatment of metastatic cancers
From MaRDI portal
Publication:1790751
DOI10.1016/j.jtbi.2013.06.036zbMath1397.92312arXiv1306.4842OpenAlexW2962783505WikidataQ45998827 ScholiaQ45998827MaRDI QIDQ1790751
Sébastien Benzekry, Philip Hahnfeldt
Publication date: 4 October 2018
Published in: Journal of Theoretical Biology (Search for Journal in Brave)
Full work available at URL: https://arxiv.org/abs/1306.4842
Applications of optimal control and differential games (49N90) Medical applications (general) (92C50)
Related Items (14)
Dynamical properties of a minimally parameterized mathematical model for metronomic chemotherapy ⋮ Limiting the development of anti-cancer drug resistance in a spatial model of micrometastases ⋮ Why Is Evolution Important in Cancer and What Mathematics Should Be Used to Treat Cancer? Focus on Drug Resistance ⋮ Asymptotic analysis and optimal control of an integro-differential system modelling healthy and cancer cells exposed to chemotherapy ⋮ Optimal control of cancer chemotherapy with delays and state constraints ⋮ A mathematical model of low grade gliomas treated with temozolomide and its therapeutical implications ⋮ Game theory for managing evolving systems: challenges and opportunities of including vector-valued strategies and life-history traits ⋮ Optimal control to develop therapeutic strategies for metastatic castrate resistant prostate cancer ⋮ Mathematical analysis and simulation study of a phase-field model of prostate cancer growth with chemotherapy and antiangiogenic therapy effects ⋮ Optimal control of cytotoxic and antiangiogenic therapies on prostate cancer growth ⋮ Optimization of an \textit{in vitro} chemotherapy to avoid resistant tumours ⋮ Dynamics and control of a mathematical model for metronomic chemotherapy ⋮ Practically scheduling hormone therapy for prostate cancer using a mathematical model ⋮ Numerical optimal control of a size-structured PDE model for metastatic cancer treatment
Cites Work
- Unnamed Item
- Optimal scheduling of radiotherapy and angiogenic inhibitors
- A history of the study of solid tumour growth: the contribution of mathematical modelling
- Circadian rhythm and cell population growth
- Mathematical analysis of a two-dimensional population model of metastatic growth including angiogenesis
- A new mathematical model for optimizing the combination between antiangiogenic and cytotoxic drugs in oncology
- The influence of PK/PD on the structure of optimal controls in cancer chemotherapy models
- Scheduling of angiogenic inhibitors for Gompertzian and logistic tumor growth models
- Role of optimal control theory in cancer chemotherapy
- An age-and-cyclin-structured cell population model for healthy and tumoral tissues
- Mathematical and numerical analysis for a model of growing metastatic tumors
- On optimal delivery of combination therapy for tumors
- A model describing the growth and the size distribution of multiple metastatic tumors
- A model for the resistance of tumor cells to cancer chemotherapeutic agents
- Chemotherapy of vascularised tumours: role of vessel density and the effect of vascular ``pruning
- Tumour eradication by antiangiogenic therapy: analysis and extensions of the model by Hahnfeldt et al. (1999)
- An elementary approach to modeling drug resistance in cancer
- Minimizing long-term tumor burden: the logic for metronomic chemotherapeutic dosing and its antiangiogenic basis
- Synchronisation and control of proliferation in cycling cell population models with age structure
- Drug resistance in cancer chemotherapy as an optimal control problem
- Mathematical and numerical analysis of a model for anti-angiogenic therapy in metastatic cancers
- Modeling the Impact of Anticancer Agents on Metastatic Spreading
- AntiAngiogenic Therapy in Cancer Treatment as an Optimal Control Problem
- Realizable protocols for optimal administration of drugs in mathematical models for anti-angiogenic treatment
This page was built for publication: Maximum tolerated dose versus metronomic scheduling in the treatment of metastatic cancers
